Birchview Capital’s Myriad Genetics MYGN Stock Holding History

Birchview Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-30,000	Closed	-$817K	–	49
2019 Q4	$817K	Hold	30,000	–	–	0.59%	27
2019 Q3	$859K	Buy	30,000 +10,000	+50%	+$291K	0.57%	17
2019 Q2	$556K	Hold	20,000	–	–	0.34%	31
2019 Q1	$664K	Buy	20,000 +10,000	+100%	+$304K	0.42%	22
2018 Q4	$291K	Hold	10,000	–	–	0.28%	38
2018 Q3	$460K	Hold	10,000	–	–	0.3%	37
2018 Q2	$374K	Hold	10,000	–	–	0.25%	36
2018 Q1	$296K	Buy	+10,000	New	+$338K	0.19%	37

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Birchview Capital's MYGN Position: Q1 2020 in Review

Birchview Capital sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 30,000 shares — an estimated $817K sold.

Birchview Capital first reported a position in MYGN in Q1 2018 and held it in 8 quarters. The position peaked at $859K in Q3 2019. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

Birchview Capital reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
Birchview Capital sold 30,000 Myriad Genetics shares in Q1 2020, an estimated $817K.
Birchview Capital first reported a position in Myriad Genetics in Q1 2018 and held it in 8 quarters.
Birchview Capital's Myriad Genetics position peaked at $859K in Q3 2019.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Birchview Capital's 13F filing for Q1 2020, filed 12 May 2020.